高コレステロール血症におけるスタチンのプレイオトロプ効果:リポプロテオミクスベースのアプローチを用いた前向きな観察研究
Sanjay Bhandari1, Pankaj Gupta2, Paulene Quinn1
1Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK.
Lancet (London, England)
|August 28, 2015
まとめ
スタチンは脂質タンパク質の負荷を変化させ,細胞骨格の組織,炎症,抗酸化防御に影響します. この研究は,スタチン誘発のアディプシン低下と糖尿病のリスクとの潜在的な関連性を明らかにしています.
科学分野:
- 心血管疾患の研究
- プロテオミクス
- 脂質代謝
背景:
- スタチンは,脂質低下およびプレオトロピク作用により,心血管疾患の予防薬として確立されています.
- リポタンパク質の役割は,脂質輸送を超えて,タンパク質の荷物を介して凝固,炎症,酸化還元反応を含む.
- 高コレステロール血症の治療には,しばしばスタチン療法が含まれます.
研究 の 目的:
- スタチン療法が脂質タンパク質に与える影響を調査する.
- これらの変化を分析するために,偏りのないボトムアッププロテオミクスのアプローチを使用します.
- 高コレステロール血症の患者におけるスタチンのプレイオトロプ効果を調査する.
主な方法:
- スタチン治療を開始した高コレステロール患者11人を対象とした前向きな観察研究.
- 治療開始時と2ヶ月後に採取された血サンプル.
- タンパク質分析に使用される高解像度離子運動タンデム質量スペクトロメトリーと組み合わせたラベルのない二次元液体クロマトグラフィー.
主要な成果:
- スタチン治療後の218のタンパク質のうち33のタンパク質が有意な差異表現を示した.
- 細胞骨組織,抗酸化,および抗炎症機能に関与するタンパク質を含む.
- アポリポプロテインB100,アディプシン,幹細胞成長因子を含む低調タンパク質は,インスリン分泌と血液形成に新しい効果を示唆しています.
結論:
- スタチンの治療は細胞骨格の構造を改造し,抗炎症,抗酸化,および増殖抑制効果を発揮し,内皮機能不全を潜在的に制限する.
- アディプシンを低下させることが,スタチンの使用と糖尿病の発症との論争の的関連を説明するかもしれない.
- この研究は,スタチンの有益な効果と潜在的に有害な効果の両方についての理解を深める.
さらに関連する動画
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Cholesterol: Significance and Regulation
1.9K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.9K
Pharmacogenomics: Identification of New Drug Targets
86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Atherosclerosis III: Management
589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
Pleiotropy
44.1K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
44.1K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
257
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257


